# US 2017/0253590 A1 · Small molecule ire1-alpha inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253590 A1
- Document ID: US20170253590A1
- Status: Published application
- Kind: A1
- Application number: 15/449,547
- Filed: 2017-03-03
- Published: 2017-09-07
- Earliest claimed: 2016-03-03
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Laurie H. Glimcher; Sarah Elizabeth Bettigole; Juan Rodrigo Cubillos Ruiz; Joseph P. Vacca
- Web page: https://patentgrep.com/patent/US20170253590A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 407/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are IRE1α inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.

## Claims

### Claim 1

A compound of formula I,
wherein:
A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x R1 substituents;
C is phenyl or pyridinyl;
D is heterocyclyl ring;
linkage1 is a single bond between A and B;
linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;
y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;
x is an integer of 0-4;
v is an integer of 0-2;
R1 substituents on the A ring are selected from amino, optionally substituted C1-C4 alkyl, optionally substituted ether, optionally substituted C1-C4 alkoxy, oxy, hydroxy, —NH—SO2-phenyl-(R5), and cyano;
R2 substituents on the B ring are selected from amino, and optionally substituted C1-C4 alkyl;
R3 substituents on the C ring are selected from halo, CF3, optionally substituted C1-C4 alkyl, and optionally substituted heteroaryl; and
R4 substituents on the D ring are selected from optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, (optionally substituted C1-C4 alkylene)-OH, hydroxy, optionally substituted aryl, optionally substituted benzyl, and optionally substituted benzaldehyde; and
R5 is halo; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the A ring is heteroaromatic,

### Claim 3

The compound of claim, wherein the A ring is a fusion of two rings.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the A ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, and quinazolinyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the B ring is a single, non-fused ring.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the B ring is pyrazolyl, imidazolyl, or triazolyl.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The compound of claim 1, wherein the C ring is phenyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the linkage2 is selected from:
wherein a hydrogen atom on Ring B replaced by the first terminal atom of linkage2 and a hydrogen atom on Ring C is replaced by the second terminal atom of linkage2.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the D ring is a heterocyclyl ring containing at least one N atom.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the D ring is piperidinyl, piperazinyl, or morpholinyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the R1 substituents on the A ring are selected from amino and optionally substituted C1-C3 alkyl.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The compound of claim 1, wherein x=0, x=1, or x=2.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The compound of claim 1, wherein the R3 substituent on the C ring is CF3 or wherein the R4 substituents on the D ring are selected from CH3, CH3CHCH3, CH3CH(CH2)CH3, and CH3CH2CH3OH.

### Claim 18

(canceled)

### Claim 19

A compound of formula Ia:
wherein,
A1 is N, CH, or CR1; A2 is N, CH, or CR1; A3 is N, CH, or CR1; A4 is N, CH, or CR1; A5 is N, CH, or CR1; A6 is N, CH, or CR1; A7 is N CH, or CR1;
v is an integer of 0-2;
each R1 is NH2 or OH; provided that the number of R1 on the A ring does not exceed 4;
B is selected from:
each R2 is independently selected from H and optionally substituted C1-C4 alkyl;
X1 and X2 are each independently CH2 or NH; with the provision that X1 and X2 are not each CH2,
R3 is selected from H, halo, CF3, optionally substituted C1-C4 alkyl, and optionally substituted heteroaryl;
D is a heterocyclyl ring containing at least one N atom; and
each R4 is selected from H, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, (optionally substituted C1-C4 alkylene)-OH, hydroxy, optionally substituted aryl, and optionally substituted benzyl; or
a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The compound of claim 19, wherein A1 is CH or CR1; A2 is N; A3 is CH or CR1; A4 is N, CH, or CR1; A5 is CH or CR1, A6 is CH or CR1; and A7 is CH or CR1.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 19)

The compound of claim 19, wherein B
and each R2 is independently H or methyl.

### Claim 24

(canceled)

### Claim 25 (depends on 19)

The compound of claim 19, wherein X1 and X2 are each NH; X1 is CH2 and X2 is NH, or X1 is NH and X2 is CH2.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 19)

The compound of claim 19, wherein R3 is selected from H, halo, and CF3.

### Claim 29

(canceled)

### Claim 30 (depends on 19)

The compound of claim 19, wherein D is selected from:

### Claim 31 (depends on 19)

The compound of claim 19, wherein v is 1; and R4 is selected from H, optionally substituted C1-C4 alkyl, (optionally substituted C1-C4 alkylene)-OH, hydroxy, optionally substituted aryl, and optionally substituted benzyl.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 19)

A composition comprising a carrier and a compound of claim 19

### Claim 38

(canceled)

### Claim 39 (depends on 19)

A method for treating or reducing cancer, comprising:
administering to a subject in need thereof, the compound of claim 19.

### Claim 40 (depends on 19)

A method for clearing cancer cells, comprising: administering to a subject in need thereof, the compound of claim 19.
